Full-Time

Medical Science Liaison / Senior Medical Science Liaison

Phathom Pharmaceuticals

Phathom Pharmaceuticals

201-500 employees

Develops and markets acid-related GI therapies

Compensation Overview

$170k - $220k/yr

+ Equity compensation + Employee Stock Purchase Plan

Remote in USA + 1 more

More locations: Texas, USA

Hybrid

Remote role with 30–50% travel and driving within the assigned territory; some territories may require air travel.

Master's, PharmD, PhD, MD

Category
Biology & Biotech (1)

Get referred to Phathom Pharmaceuticals

See people who can refer or advise you

Requirements
  • An advanced degree in life sciences, such as MD, PharmD, PhD, DNP, PA-C, or MSN, is required.
  • Knowledge of PhRMA, American Gastroenterological Association, and other relevant guidelines is required.
  • A good understanding of the clinical development process and International Council for Harmonisation Good Clinical Practice guidelines is required.
  • The role requires the ability to maintain scientific credibility while being commercially supportive.
  • The role requires excellent verbal and written communication and presentation skills.
  • The role requires the ability to drive within an assigned territory by automobile and, in some territories, travel by airplane.
  • The role requires the ability to work collaboratively across geographic areas and cross-functional groups.
  • The role requires the ability to operate in a fast-paced, innovative environment while remaining proactive, resourceful, and efficient.
Responsibilities
  • Develop and enhance professional relationships with medical thought leaders involved in various phases of product development.
  • Provide medical information through fair-balanced scientific exchange and clinical or scientific support for Phathom and Medical Affairs.
  • Identify, develop, and maintain collaborative relationships with current and future Key Opinion Leaders and healthcare stakeholders in strategically important disease states.
  • Provide clinical presentations and information in response to unsolicited questions in academic, community, and healthcare provider settings.
  • Collaborate with Clinical to enhance patient enrollment in Phathom-sponsored clinical trials by identifying appropriate trial sites and interacting with investigators.
  • Act as a primary liaison to investigators interested in developing and performing investigator-initiated research.
  • Develop and execute territory plans aligned with strategic regional and national plans of action.
  • Assess the market landscape and competitive intelligence, including therapeutic trends and unmet needs, and provide timely feedback on emerging clinical and scientific information.
  • Gather insights from Key Opinion Leaders, healthcare providers, and clinical trial investigators and share feedback with cross-functional stakeholders.
  • Provide scientific support at medical congresses.
  • Develop an understanding of Key Opinion Leader needs and network within the pharmaceutical or biopharmaceutical organization and territory.
  • Identify institutional opportunities and liaise appropriately for Key Opinion Leader interests.
  • Establish internal working relationships across functions.
  • Align with Medical Science Liaison team strategy by examining current initiatives and processes in the evolving industry and competitive landscape.
  • Proactively identify research opportunities addressing unmet needs and troubleshoot administrative or recruitment barriers.
  • Maintain expertise in Phathom products and disease states within the franchise portfolio.
  • Analyze proposed trial designs critically and provide feedback.
  • Encourage and lead open exchanges of information and viewpoints.
  • Communicate issues proactively and negotiate with cross-functional teams to reach optimal solutions.
  • Provide high-quality scientific information to healthcare professionals.
  • Respond to unsolicited medical information requests in the field.
  • Initiate and maintain strong relationships with Key Opinion Leaders.
  • Maintain medical expertise and understanding of clinical practice in acid-related gastrointestinal disorders and gather field insights regarding product characteristics and therapeutic area development.
  • Use national and regional medical plans to develop and align tactical plans for the assigned geography.
  • Support educational meetings focused on acid-related gastrointestinal disorders.
  • Interact with healthcare provider speakers to provide briefings on compliance, product information, clinical and scientific data, and presentation development.
  • Represent assigned products and therapeutic areas according to ethical and professional standards and relevant guidelines.
Desired Qualifications
  • Prior or current participation in a Medical Affairs Fellowship or Internship is preferred.
  • Medical Science Liaison experience is preferred.
  • Prior work experience in pharmaceutical Medical Affairs or as a healthcare provider is strongly preferred.
  • Product launch experience is preferred.
  • Therapeutic area experience in gastrointestinal diseases is preferred.
  • Knowledge of competitive products and their place in treatment algorithms is preferred.
  • Flexibility in applying scientific knowledge to secondary pipeline therapeutic areas is preferred.
Phathom Pharmaceuticals

Phathom Pharmaceuticals

View

Phathom Pharmaceuticals develops and commercializes medicines for acid-related gastrointestinal disorders, focusing on adult patients with conditions like erosive esophagitis and heartburn. Its flagship product is VOQUEZNA (vonoprazan), a prescription treatment designed to heal damage in the esophagus and relieve heartburn symptoms. The company differentiates itself by concentrating on specialized GI therapies and bringing its prescription medicines to market for patients who need them, through research, development, and commercialization activities. Phathom’s goal is to provide effective, compliant treatments that improve outcomes for people suffering from acid-related GI diseases.

Company Size

201-500

Company Stage

IPO

Headquarters

Florham Park, New Jersey

Founded

2018

Get referred to Phathom Pharmaceuticals

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue reached $74.3 million, up 88% year over year.
  • Phathom expanded to more than 290 reps by April 30, 2026.
  • Topline EoE data arrives in Q4 2026, offering a second indication.

What critics are saying

  • July 30, 2026 guidance fell to $310 million-$325 million after access friction.
  • Levi & Korsinsky launched a July 30, 2026 securities investigation over that cut.
  • A 2027 tegoprazan launch ends Phathom's U.S. P-CAB monopoly.

What makes Phathom Pharmaceuticals unique

  • VOQUEZNA holds U.S. exclusivity through May 3, 2032, after Phathom's 2025 citizen petition.
  • Phathom completed 95-patient Phase 2 EoE enrollment on June 23, 2026.
  • The company sells VOQUEZNA, DUAL PAK, and TRIPLE PAK across GERD and H. pylori.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Company Match

Company Equity

Employee Stock Purchase Plan

Parental Leave

Hybrid Work Options

Unlimited Paid Time Off

Paid Holidays

Wellness Program

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Employee Stock Purchase Plan

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-2%

2 year growth

-2%
MarketBeat
Aug 2nd, 2026
925,000 shares in Phathom Pharmaceuticals, Inc. $PHAT purchased by Perceptive Advisors LLC.

925,000 shares in Phathom Pharmaceuticals, Inc. $PHAT purchased by Perceptive Advisors LLC. August 2, 2026 Key points. * Perceptive Advisors acquired 925,000 Phathom shares worth approximately $10.3 million, establishing a 1.16% stake. Institutional investors collectively own 99.01% of the company. * Phathom reported second-quarter revenue of about $74.3 million, exceeding estimates, but lowered its 2026 revenue guidance to $310 million-$325 million, below consensus and its prior outlook. * Analysts maintain a generally positive view, with a "Moderate Buy" consensus and average price target of $23.43 versus the stock's recent $8.75 price; however, a securities-law investigation related to the guidance cut adds risk. * MarketBeat previews top five stocks to own in September. Perceptive Advisors LLC acquired a new position in shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 925,000 shares of the company's stock, valued at approximately $10,277,000. Perceptive Advisors LLC owned about 1.16% of Phathom Pharmaceuticals as of its most recent SEC filing. Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. SummitTX Capital L.P. grew its stake in shares of Phathom Pharmaceuticals by 92.3% during the first quarter. SummitTX Capital L.P. now owns 995,885 shares of the company's stock valued at $11,064,000 after purchasing an additional 478,065 shares during the last quarter. Hussman Strategic Advisors Inc. bought a new position in Phathom Pharmaceuticals in the 4th quarter worth approximately $2,439,000. Next Century Growth Investors LLC acquired a new position in Phathom Pharmaceuticals during the 4th quarter worth $6,533,000. EcoR1 Capital LLC acquired a new position in Phathom Pharmaceuticals during the 1st quarter worth $6,944,000. Finally, Stratos Wealth Partners LTD. acquired a new position in Phathom Pharmaceuticals during the 4th quarter worth $834,000. Institutional investors and hedge funds own 99.01% of the company's stock. Phathom Pharmaceuticals stock performance. Shares of Phathom Pharmaceuticals stock opened at $8.75 on Friday. The firm has a fifty day moving average of $10.77 and a two-hundred day moving average of $11.70. The stock has a market capitalization of $697.90 million, a price-to-earnings ratio of -6.84 and a beta of 0.49. Phathom Pharmaceuticals, Inc. has a 52 week low of $8.02 and a 52 week high of $18.31. Analysts set New Price targets. Several equities research analysts have recently commented on the company. HC Wainwright reissued a "buy" rating and issued a $26.00 target price on shares of Phathom Pharmaceuticals in a research note on Friday. Guggenheim cut their price target on Phathom Pharmaceuticals from $25.00 to $22.00 and set a "buy" rating on the stock in a research note on Friday. Needham & Company LLC decreased their price target on Phathom Pharmaceuticals from $28.00 to $22.00 and set a "buy" rating on the stock in a report on Thursday. Craig Hallum reissued a "buy" rating and set a $20.00 price objective on shares of Phathom Pharmaceuticals in a report on Friday. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Phathom Pharmaceuticals in a research report on Friday, July 17th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $23.43. Discover more EV Market Report Dividend Screener Tool Phathom Pharmaceuticals news summary. Here are the key news stories impacting Phathom Pharmaceuticals this week: * Positive Sentiment: Phathom reported second-quarter revenue of approximately $74.3 million, ahead of the $72.7 million analyst consensus. Earnings also improved substantially from the year-earlier period, with some reports characterizing results as breakeven, although another data source reported a loss of $0.08 per share versus expectations for a $0.06 loss. Phathom Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update * Positive Sentiment: Needham maintained a "buy" rating and set a $22 price target, implying substantial potential upside from recent trading levels. The target, however, was reduced from $28, limiting the positive impact. Phathom Pharmaceuticals Given New Price Target at Needham * Neutral Sentiment: Management is expanding its commercial organization to more than 290 sales representatives, indicating continued investment in product growth but also potentially increasing near-term operating costs. Phathom Pharmaceuticals Q2 2026 Earnings Call Transcript * Negative Sentiment: Phathom lowered its fiscal 2026 revenue guidance to $310 million-$325 million, below the roughly $334.3 million consensus estimate and below its previous high end of $345 million. The outlook reduction was the primary fundamental catalyst for the sharp decline in the stock. Phathom Pharmaceuticals Investigation Notice * Negative Sentiment: Levi & Korsinsky announced an investigation into whether Phathom may have violated securities laws in connection with its guidance update. The potential legal overhang adds further pressure following the guidance reduction. Phathom Pharmaceuticals profile. Phathom Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases. The company's core mission centers on addressing serious GI disorders by leveraging innovative mechanisms of action to improve patient outcomes. Phathom's research and development efforts concentrate on conditions such as Helicobacter pylori infection, erosive esophagitis, gastroparesis and other functional GI disorders where significant unmet medical needs persist. The company's lead asset is vonoprazan, a potassium-competitive acid blocker (P-CAB) licensed for use in the United States. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider Phathom Pharmaceuticals, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Phathom Pharmaceuticals wasn't on the list. While Phathom Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you'll find 7 stocks that could play a major role in the next tech-driven market boom.

Yahoo Finance
May 5th, 2026
Phathom Pharmaceuticals narrows Q1 loss to $30.4M and reaffirms 2026 profitability target

Phathom Pharmaceuticals reported a first-quarter 2026 net loss of $30.37 million, down from $94.32 million a year earlier, with basic loss per share narrowing to $0.37 from $1.31. The company maintained its 2026 guidance, projecting net revenues of $320 million to $345 million and targeting operating profitability, excluding stock-based compensation, by the third quarter. The narrowed loss supports the near-term profitability catalyst, though the company remains heavily reliant on its single product, VOQUEZNA. The reaffirmed guidance matters for investors monitoring cash burn and operating leverage ahead of potential capital raising. Some analysts project revenues of approximately $730 million and earnings of roughly $211 million by 2028, a more bullish outlook than consensus. Shares rose 11% following the results.

Yahoo Finance
May 2nd, 2026
Phathom Pharmaceuticals doubles Q1 revenue to $58.3M, targets $1B in annual GI sales with VOQUEZNA

Phathom Pharmaceuticals reported first-quarter net revenue of $58.3 million, up 104% year-on-year, as its acid-suppression medicine VOQUEZNA gained traction amongst gastroenterologists. The company has expanded its salesforce to over 290 representatives and is targeting $1 billion in annual gastroenterology revenue. VOQUEZNA captured approximately 45% new-to-brand share amongst the top 300 gastroenterology prescribers in the first quarter. With roughly 1.35 million prescriptions filled through mid-April, Phathom reiterated 2026 revenue guidance of $320–345 million and expects operating profitability excluding stock-based compensation by the third quarter. The company's Phase II eosinophilic oesophagitis trial is enrolling ahead of schedule, with top-line data expected late fourth quarter or early first quarter 2027. Management anticipates potential competition from tegoprazan in 2027.

Yahoo Finance
Feb 28th, 2026
Phathom Pharmaceuticals posts 217% revenue growth, targets Q3 2026 profitability

Phathom Pharmaceuticals reported 217% year-over-year revenue growth in 2025, reaching guidance through a shift towards a GI-focused sales strategy. The company reduced quarterly cash operating expenses by 50% in Q4 2025 whilst maintaining commercial momentum, with over 1.1 million total prescriptions filled. The company projects 2026 net revenue of $320 million to $345 million and expects to achieve operating profitability in Q3 2026 and for the full year, with cash operating expenses decreasing 14% at the midpoint. Cash flow positivity is anticipated in 2027. Phathom modified its term loan agreement, reducing principal to $175 million and lowering interest rates to 9.85%, with maturities extended to 2029. The company maintains approximately $190 million in cash post-modification.

Yahoo Finance
Feb 14th, 2026
Phathom Pharmaceuticals targets 2H 2026 profitability with $1B revenue goal from VOQUEZNA GI conversion

Phathom Pharmaceuticals is pivoting its commercial strategy to focus on gastroenterology, targeting operating profitability in the second half of 2026, CEO Steven Basta told the Guggenheim Emerging Outlook Biotech Summit. The company is building around VOQUEZNA (vonoprazan), which generated $55 million in 2024 revenue and an estimated $175 million in 2025. Phathom has remapped sales territories and is expanding its field team to approximately 300 representatives by the end of March. The company aims to convert 20–30% of GI proton pump inhibitor prescriptions—roughly four to six million scripts—to VOQUEZNA, which management estimates could generate about $1 billion in revenue from gastroenterology alone. A recent capital raise was designed to address debt maturities in 2027. Regulatory exclusivity for VOQUEZNA runs through May 2032, with potential extensions into 2033–2034.